Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SPRB
SPRUCE BIOSCIENCES, INC.
NASDAQ
$60.78
▼ DOWN 3.98% (-2.52)

KEY STATISTICS

Market Cap$167.28 M
52w High$240.00
52w Low$7.20
Dividend Yield—
Frequency—
P/E-1.53
Volume39.96K
Shares Out.2.75M

COMPANY

LEADERSHIP

Javier Szwarcberg
CHIEF EXECUTIVE
Javier Szwarcberg

COMPENSATION 2026

Salary$610,000
Stock Awards$1,750,518
Incentive Plan Pay$0
All Other Comp.$5,000
Total$2,910,573

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 9, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
22

PRICE TARGET

Target High$150.00
Target Low$104.00
Target Median$140.00
Target Consensus$131.33

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$50.00M
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2025-08-05Reverse1:75

PRICE

$60.78 ▼ DOWN 3.98% (−$2.52)
OVERLAYS
$60.00$61.00$62.00$63.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM60.78

About Spruce Biosciences, Inc.

https://www.sprucebio.com ↗

Spruce Biosciences develops novel therapies like tildacerfont for rare endocrine disorders, including CAH and PCOS, with multiple Phase 2b clinical trials, and has a licensing agreement with Eli Lilly.

INDUSTRY

Biotechnology

A PRODUCT SPRUCE BIOSCIENCES, INC. IS KNOWN FOR

Tralesinidase alfa
Tralesinidase alfa

Spruce Biosciences is developing an enzyme replacement therapy for Sanfilippo syndrome type B (MPS IIIB), now their lead candidate after recent acquisition, with plans for accelerated FDA approval.

COMPETITORS

COMPETITOR
BBIO COMPARE
CRNX COMPARE
ETON COMPARE
NBIX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
49
LISTED HERE
9
RANKED BY POSITION SIZE
VTS.AX
0.00% · 84.9K
XSU.TO
0.01% · 67.8K
DFAS
0.00% · 3.8K
XRSU.L
0.01% · 2.5K
QQQS
0.60% · 2.2K
RSSL
0.01% · 1.3K
AVSC
0.00% · 846
URTY
0.00% · 109
FSEG
0.06% · 66

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
40
TOP 12 OF 40 · RANKED BY POSITION SIZE
Rivervest Venture Management LLC
2.9M sh · $1.39M
Abingworth Llp
1.8M sh · $1.97M
Blackrock Inc.
124.7K sh · $64.58K
Ikarian Capital, LLC
121.4K sh · $10.57M
Millennium Management LLC
111.9K sh · $7.31M
Citadel Advisors LLC
70.0K sh · $4.57M
Wellington Management Group Llp
58.9K sh · $5.14M
Adar1 Capital Management, LLC
58.6K sh · $3.83M
Alyeska Investment Group, L.P.
51.7K sh · $3.38M
Boothbay Fund Management, LLC
47.9K sh · $4.18M
Balyasny Asset Management L.P.
40.0K sh · $2.61M
Carlyle Group Inc.
38.6K sh · $2.52M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Quartel Adrian W
Purchase · 13.0K shares
2026-07-27
★
Quartel Adrian W
— · —
2026-07-27
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Szwarcberg Javier B.
Purchase · 266 shares
2026-06-30
★
DIRECTOR
SPIEGELMAN DANIEL K
Purchase · 1.7K shares
2026-05-21

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
MARKET OUTPERFORM 2
OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY Citizens MARKET OUTPERFORM HC Wainwright & Co. BUY Leerink Partners OUTPERFORM JMP Securities MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
EQ$2.39COMPARE
OTLK$0.64COMPARE
VTVT$32.36COMPARE
OSTX$1.64COMPARE
CUE$27.88COMPARE
NRXP$3.55COMPARE
HOWL$0.94COMPARE